Business Wire

STEEPER

1.9.2021 13:09:04 CEST | Business Wire | Press release

Share
Innovation and Evolution: A New Myoelectric Upper Limb System by Steeper

In their centenary year Steeper Group, a world leading manufacturer of prosthetic devices, launch their latest myoelectric system. The full limb build is designed to offer patients and clinicians across the globe a durable, high-capacity upper limb system at an affordable cost, which harnesses the power of popular myoelectric technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005522/en/

Designed for the everyday, the Steeper Myoelectric System includes the new Myo Kinisi hand which provides an easy to control, high-speed grasp alongside a strong grip force to carry out activities of daily living with ease, with the added benefit of an Auto-Grip function allowing users a more secure grip on difficult to hold objects. The hand is complemented by advanced myoelectrodes for increased accuracy and gain control, and is powered by the all new high-capacity S-Charge System which features a 3500mAh internal battery, making it one of the most powerful available. The prosthesis is finished by the ‘Elegance Plus’ cosmetic glove, designed specifically to complement the Myo Kinisi.

Paul Steeper, CEO of Steeper Group and SteeperUSA commented “a new myoelectric system is something our customers have desired for some time. We’ve used our innovative knowledge of upper limb prostheses to deliver an evolution to a myoelectric system; using the latest advancements in product design, super capacitor technology and modern materials such as titanium for increased strength.”

Patients will enjoy the enhanced cosmesis given by the Elegance Plus silicone glove which has been designed to work in harmony with the Myo Kinisi. An internal reinforced mesh layer increases durability for even high activity users, and improved realism to the skin appearance is achieved with enhancement on the knuckles, joints and nail finish; the Elegance Plus Glove is available in 19 TrueFinishTM shades.

Clinicians can program the Myo Kinisi to meet exacting patient preferences with a choice of five modes and fine adjustments to control parameters can be made via the Steeper Configuration Device, a simple three button operation programming hub with an easy-to-read screen.

Paul Steeper concluded “the Steeper Myoelectric System will offer both clinicians and users a greater choice of durable, reliable and easy to use devices. The Myo Kinisi offers superb grip strength via trusted technology and the Elegance Plus Glove is sure appeal to a wide range of users with its enhanced finish and skin-like texture; couple that with our very latest myoelectrodes and increased capacity S-Charge battery system and users will instantly benefit from these innovations. Patient trials have proved successful with users commenting on the increased control the Myo Kinisi offers whilst using a control strategy they are already familiar with; meaning the hand is easily and readily usable.”

ENDS

Notes to editors:

Steeper Group trade as SteeperUSA within the United States and Canada.

For more information on the Steeper Myoelectric System or any of our upper limb prosthetic products, please visit www.steepergroup.com or www.steeperusa.com .

Image caption: The Steeper Upper Limb Build offers a secure grip, an enhanced cosmetic appearance and is powered by one of the most powerful battery systems on the market.

Link:

ClickThru

Social Media:

https://www.facebook.com/SteeperGroup

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye